viTAmin K2 and rEcOVery From ExeRcise

Not Applicable

Completed

• Conditions: Oxidative Stress; Strength; Vitamin K; Exercise; Inflammation; Recovery
• Interventions: Dietary Supplement: Vitamin K2; Dietary Supplement: Micro-crystalline cellulose

• Registration Number: NCT04676958
• Lead Sponsor: University of Glasgow

Brief Summary

The aim of the current study, therefore, is to investigate the effects of vitamin K2 supplementation on the physiological responses to an acute bout of resistance exercise.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-11-24
• Study First Submitted QC: 2020-12-18
• Study First Posted: 2020-12-21
• Study Start: 2021-04-01
• Primary Completion: 2023-07-01
• Study Completion: 2023-07-01
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-26
• Last Update Posted: 2023-11-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• Participant is able and willing to sign the Informed Consent From
• No plans to change lifestyle (activity and nutrition) during the study period
• Older group (n=40): 65 years of age or older.
• Younger group (n=40): Aged 18-40 years

Exclusion Criteria

• Not currently, or in the last year, participating in more than 1h per week of vigorous aerobic physical activity or any resistance exercise
• BMI > 30 kg/m2
• diabetes
• severe cardiovascular disease
• seizure disorders
• liver disease
• uncontrolled hypertension (>150/90mmHg at baseline measurement)
• cancer or cancer that has been in remission <5 years
• ambulatory impairments which would limit ability to perform assessments of muscle function
• dementia
• currently taking Vitamin K2 supplements
• currently taking Vitamin K antagonists/anticoagulants (e.g. warfarin)
• current smoking
• history of drug abuse
• taking medication known to affect muscle (e.g. steroids).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vitamin K2	Vitamin K2	380 mg capsule/day micro-crystalline cellulose including 240ug/day Vitamin K2
Placebo	Micro-crystalline cellulose	380 mg capsule/day micro-crystalline cellulose

Primary Outcome Measures

Name	Time	Method
Change in post exercise recovery of muscle strength	Change from baseline to 12 weeks	Muscle strength (MVC) of the knee extensor muscles will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise

Secondary Outcome Measures

Name	Time	Method
Change in pain free range of motion during knee extension exercise	Change from baseline to 12 weeks	The range of motion which is pain free will be measured during knee extension using a goniometer before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Change in post exercise recovery of sEMG activity	Change from baseline to 12 weeks	Quadriceps muscle sEMG will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Change in post exercise interleukin-6	Change from baseline to 12 weeks	Circulating interleukin-6 will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Change in Carboxylated Osteocalcin levels	Change from baseline to 12 weeks	Carboxylated Osteocalcin will be measured in baseline and 12 week samples
Change in post exercise recovery of functional abilities	Change from baseline to 12 weeks	Time to complete 5 chair rises will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Change in post exercise peroxiredoxin 3 redox state	Change from baseline to 12 weeks	Circulating peroxiredoxin 3 redox state will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise
Change in vitamin K levels	Change from baseline to 12 weeks	Vitamin K will be measured in baseline and 12 week samples
Change in uncarboxylated Osteocalcin levels	Change from baseline to 12 weeks	uncarboxylated Osteocalcin will be measured in baseline and 12 week samples
Change in dephosphorylated-uncarboxylated matrix gla-protein levels	Change from baseline to 12 weeks	dephosphorylated-uncarboxylated matrix gla-protein will be measured in baseline and 12 week samples
Change in carboxylated matrix gla-protein levels	Change from baseline to 12 weeks	carboxylated matrix gla-protein will be measured in baseline and 12 week samples
Change in post exercise F2 isoprostanes	Change from baseline to 12 weeks	Circulating F2 isoprostanes will be measured before and after (3h, 24h, 48h, 72h) an acute bout of resistance exercise

Trial Locations

Locations (2)

University of Glasgow; 🇬🇧 Glasgow, United Kingdom

Stuart Robert Gray; 🇬🇧 Glasgow, United Kingdom